I felt low a few weeks after starting the pill. Was it the pill?

A single personal experience cannot be separated from coincidence by statistics alone. The Danish cohort did find that the rate ratio for antidepressant use peaked about six months after starting, at 1.4, which is consistent with an early effect in some people. A dated diary of mood and start date gives a clinician something concrete to work with.

Which method had the highest depression estimates in these studies?

Non-oral progestin methods, not the standard combined pill. The Danish cohort reported 2.0 for the transdermal patch and 1.4 for the levonorgestrel intrauterine system. The Swedish cohort reported 1.59 for the levonorgestrel intrauterine device and 1.38 for the implant among adolescents. Both sets of authors cautioned that people choosing these methods differ from those who do not.

Does a past depression diagnosis rule out hormonal birth control?

No. The CDC U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 places depressive disorders in Category 1 for every hormonal method, meaning no restriction on use. The guidance does note that people taking psychotropic medication or St. John's wort should have drug interactions checked.

How would a clinician confirm PMDD rather than depression?

By charting, not by a single visit. DSM-5 requires prospective daily symptom ratings across at least two consecutive menstrual cycles. The pattern has to show symptoms in the week before menses that improve within a few days of bleeding and fade in the following week.

Can Birth Control Or Hormonal Changes Cause Depression?

Q: Is any birth control pill approved to treat mood symptoms?

Yes, for one specific diagnosis. YAZ, which combines 3 mg of drospirenone with 0.02 mg of ethinyl estradiol, is FDA-approved to treat the symptoms of premenstrual dysphoric disorder in people who choose an oral contraceptive for contraception. The label states that effectiveness beyond three menstrual cycles has not been evaluated.

The short answer: Large national studies link hormonal contraception to a small rise in later antidepressant use, and the rise is largest in teenagers. The absolute gap in the biggest study was 2.2 versus 1.7 first antidepressant prescriptions per 100 person-years. A second national study found no association for the combined pill, and the one randomized trial found no significant effect on depressed mood. The hormone link is clearer after childbirth and during perimenopause.

What did the largest studies actually find?

The most quoted study is a Danish nationwide cohort published in JAMA Psychiatry in 2016. It followed 1,061,997 women and adolescents aged 15 to 34 who had no depression diagnosis and no antidepressant prescription at the start. Mean follow-up was 6.4 years.

Compared with non-users, users of combined oral contraceptives had a rate ratio of 1.23 (95% CI, 1.22 to 1.25) for a first antidepressant prescription. Progestogen-only pill users had a rate ratio of 1.34. The ratios fell as age rose. Among 15 to 19 year olds, combined pill users had a rate ratio of 1.8 and progestin-only pill users 2.2. Risk peaked about six months after starting, at 1.4.

A Swedish register study published in BJOG in 2022 reached a different conclusion about the pill. It covered 739,585 women aged 15 to 25 between 2010 and 2017 who had no prior antidepressant use and no psychiatric diagnosis. After adjustment for age, the medical reason for use, and parental psychiatric history, combined oral contraceptive users had a relative risk of 0.89 (95% CI, 0.87 to 0.91). Among adolescents the figure was 0.96.

One randomized placebo-controlled trial has tested the question directly. In a 2017 trial in Fertility and Sterility, 340 healthy women aged 18 to 35 took either a pill with 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol or a placebo for three months. General well-being fell by 4.12 points against placebo (95% CI, -7.18 to -1.06). Scores for depressed mood and for depressive symptoms did not change significantly.

How large is the absolute risk, not the relative risk?

A rate ratio of 1.23 sounds alarming. The underlying rates are the more useful numbers.

In the Danish cohort, the crude rate of a first antidepressant prescription was 2.2 per 100 person-years among hormonal contraceptive users and 1.7 per 100 person-years among non-users. That gap is roughly 5 extra prescriptions per 1,000 women per year. For a first depression diagnosis at a psychiatric hospital, the rates were 0.3 and 0.28 per 100 person-years, a difference of about 0.2 per 1,000 women per year.

These are observational figures, so they show association, not cause. People who start a hormonal method differ from people who do not. Some start it for heavy bleeding, acne, or painful periods. The Danish authors wrote that their results suggest depression as a potential adverse effect, not a proven one. The Swedish authors warned that residual confounding must shape any reading of their numbers too.

Does the formulation or delivery route matter?

Both national studies found their highest estimates for non-oral progestin methods rather than the standard combined pill.

Danish cohort, first antidepressant use: transdermal patch 2.0, vaginal ring 1.6, levonorgestrel intrauterine system 1.4.
Swedish cohort, adolescents: patch or vaginal ring 1.43, implant 1.38, levonorgestrel intrauterine device 1.59, progestogen-only pill 1.13.

Two independent registers agreeing is notable, but not proof of cause. Long-acting methods more often go to people with heavy bleeding, a recent pregnancy, or harder social circumstances, and each of those raises depression risk on its own. No trial has randomized people to a patch, an implant, or an intrauterine device and measured mood.

What do FDA labels say about mood?

Labels treat mood change as a recognized effect without claiming it is common. The YAZ label states that women with a history of depression should be carefully observed and the drug discontinued if depression recurs to a serious degree.

The label for norgestimate and ethinyl estradiol reports mood disorders, including mood alteration and depression, in 3.8% of clinical trial participants. Mood disorders led 1.1% of participants to stop treatment.

The same drug class also carries a mood indication. YAZ is approved to treat the symptoms of premenstrual dysphoric disorder in people who choose an oral contraceptive for contraception. The label adds that effectiveness beyond three menstrual cycles has not been evaluated.

A depression diagnosis is not treated as a reason to avoid these methods. The CDC U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 places depressive disorders in Category 1 for every hormonal method, which means no restriction on use. If you are weighing what to do about low mood itself, see our comparison of depression treatment options.

How is PMDD different from depression?

Premenstrual dysphoric disorder is its own DSM-5 diagnosis, not a mild form of major depression. Symptoms appear in the final week before menstruation, start to improve within a few days of bleeding, and become minimal or absent in the week after menses.

Diagnosis requires at least five of eleven symptoms, including at least one of four core symptoms: depressed mood, anxiety or tension, mood swings, or anger and irritability. It also requires prospective daily symptom ratings across at least two consecutive cycles, which is why a single bad month does not qualify.

The DSM-5 work group put prevalence at 2% to 5% of premenopausal women, and DSM-5 itself cites a wider range of roughly 3% to 8%. Timing is the distinguishing feature. Major depression does not clear a few days after a period starts. Anxiety and tension often travel with the mood symptoms, so PMDD is sometimes mistaken for an anxiety disorder; our sister site anxiety.md covers that overlap.

What about the postpartum period and perimenopause?

Here the hormone link rests on firmer ground. The CDC reports that about 1 in 8 women with a recent live birth report symptoms of postpartum depression. NIMH notes that most episodes of perinatal depression begin within 4 to 8 weeks after the birth, and lists hormone changes during and after pregnancy among the contributing factors. Our guide to postpartum depression signs and treatment covers what to watch for.

Treatment approvals support a hormonal mechanism. On August 4, 2023, the FDA approved zuranolone, a 14-day once-daily course, as the first pill for postpartum depression in adults. It acts on the receptor system targeted by a progesterone-derived neurosteroid.

A 2023 Danish cohort study ties the phases together. Among 188,648 first-time mothers, those whose earlier depression had started within six months of beginning hormonal contraception had higher odds of postpartum depression than those whose earlier depression was unrelated to starting a method (adjusted odds ratio 1.35; 95% CI, 1.17 to 1.56). The authors read this as evidence of a hormone-sensitive subgroup rather than a population-wide effect.

Perimenopause is described as a window of vulnerability. A review of longitudinal cohorts found depressed mood roughly 30% to three times more likely during the menopause transition than before it, and women with a past depression were nearly five times more likely to meet criteria for major depression during the transition. A 2018 expert panel convened by the North American Menopause Society concluded that antidepressants and psychotherapy are the front-line treatments. Estrogen therapy is not approved for perimenopausal depression, though it shows antidepressant effects in perimenopausal women who also have hot flashes.

The bottom line

Hormones can move mood, and some people are clearly more sensitive to hormonal shifts than others. For hormonal contraception, the signal is small in absolute terms, largest in adolescents, inconsistent between the Danish and Swedish registers, and absent for depressed mood in the one randomized trial. Postpartum and perimenopausal depression risk is better established, and both have treatment paths.

If your mood changed after starting a method, or if low mood tracks your cycle, a dated symptom diary is the single most useful thing to bring to a clinician. Low mood also shows up in ways people do not label as depression, which our piece on depression symptoms you might not recognize walks through.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Do not start or stop any contraceptive, hormone therapy, or antidepressant based on this page. Talk with a clinician who knows your history, and seek urgent help if you have thoughts of harming yourself.